EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers

Esra Cicek1, Ayca Circir1, Merve Oyken1,2

  • 1Department of Biological Sciences, Middle East Technical University (METU), Dumlupinar Blv No:1, Universiteler Mah., Cankaya, 06800, Ankara, Turkey.

Oncogene
|October 31, 2021
PubMed

Insights

Sorting Nexin 3 (SNX3) is crucial in the epidermal growth factor receptor (EGFR) network in triple-negative breast cancers (TNBCs). Loss of SNX3 leads to EGFR overexpression, promoting cancer progression and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Epidermal growth factor receptor (EGFR) is vital in epithelial cells and implicated in cancers like triple-negative breast cancer (TNBC).
  • Understanding EGFR networks is key to developing effective therapies and overcoming drug resistance.

Purpose of the Study:

  • To identify critical players in the epidermal growth factor (EGF) stimulated EGFR network in TNBCs.
  • To investigate the role of Sorting Nexin 3 (SNX3) in regulating EGFR activity and its implications in TNBC progression.

Main Methods:

  • Proximity labeling to assess SNX3-EGFR interactions upon EGF stimulation.
  • RNA interference (RNAi) to study the effects of SNX3 downregulation on EGFR levels and TNBC cell behavior.
  • Analysis of patient data correlating SNX3 and EGFR mRNA levels with patient survival.

Main Results:

  • SNX3 is an immediate and sustained target of EGF, increasing in abundance at both protein and transcriptional levels.
  • SNX3 interacts with and colocalizes with EGFR, early endosomes, and endocytosed EGF.
  • SNX3 loss leads to EGFR overexpression, increased proliferation, migration, invasion in TNBC cells, and enhanced tumor growth and metastasis.
  • Low SNX3 and high EGFR mRNA levels correlate with poor relapse-free survival in breast cancer patients.

Conclusions:

  • SNX3 is a critical regulator of the EGFR network in TNBCs.
  • SNX3's role in EGFR regulation has implications for other EGFR-dependent cancers.
  • Targeting SNX3 may offer a therapeutic strategy for TNBC and other related cancers.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K